SGLT2 Inhibitors Reduce Anemia Risk in Concomitant T2D, CKD
Initiating treatment with SGLT2 inhibitors vs GLP-1 RAs was linked to a 19% reduced risk for composite anemia outcomes in patients with T2D and CKD stages I-III.
Source: medscape.com
Page 13 - Pharmaceutical Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Pharmaceutical Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Pharmaceutical Sciences Today - Breaking & Trending Today
Academic changes delayed; abortion to be put on ballot; UM hires new health dean
Provost office pushes back playbook deadline
Source: montanakaimin.com
Alterity Therapeutics to Present New Data on ATH434 at the
MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”),...
Source: globenewswire.com
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 -- Alterity Therapeutics , a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today...
Source: marketscreener.com
Merck paying up to $208M to buy UB cancer research startup
Abceutics Inc., a startup preclinical-stage biopharmaceutical company spun out of a laboratory at the University at Buffalo, is being purchased as part of an up-to-$208 million agreement with biopharmaceutical giant
Source: buffalonews.com